Share Prices & Company Research

Market News

31 May 2019 | 09:04

NetScientific welcomes positive trial results from portfolio company ProAxsis

NetScientific said portfolio company ProAxsis had received positive early data from a major clinical trial funded by the British Lung Foundation and the European Respiratory Society.

'This encouraging data published in the renowned European Respiratory Journal demonstrates ProAxsis' ability to monitor bacterial infections in real time in patients suffering from lung diseases,' chief executive Ian Postlethwaite said.

'NEATstik has the potential to provide clinicians with a test identifying those at risk of further exacerbations providing more targeted care.'

'We believe that ProAxsis has the potential to become a significant player in the growing point-of-care respiratory testing market.'

At 9:04am: (LON:NSCI) Netscientific Plc share price was +3.25p at 11.75p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.